Do analysts recommend TXMD or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ASBP or QUCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ASBP or QUCY more profitable?

Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% Mainz Biomed N/A N/A N/A

Does the media favor ASBP or QUCY?

In the previous week, Mainz Biomed had 1 more articles in the media than Aspire Biopharma. MarketBeat recorded 3 mentions for Mainz Biomed and 2 mentions for Aspire Biopharma. Aspire Biopharma's average media sentiment score of 0.38 beat Mainz Biomed's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ASBP or LITS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASBP or LITS more profitable?

Aspire Biopharma's return on equity of 0.00% beat Lite Strategy's return on equity. Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% Lite Strategy N/A -90.81% -89.33%

Does the media favor ASBP or LITS?

In the previous week, Lite Strategy had 3 more articles in the media than Aspire Biopharma. MarketBeat recorded 5 mentions for Lite Strategy and 2 mentions for Aspire Biopharma. Lite Strategy's average media sentiment score of 0.57 beat Aspire Biopharma's score of 0.38 indicating that Lite Strategy is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lite Strategy 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ASBP or RKTO?

Rocket One Inc. Common Stock has a consensus price target of $5.00, indicating a potential upside of 395.05%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Rocket One Inc. Common Stock is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rocket One Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ASBP or RKTO more profitable?

Aspire Biopharma's return on equity of 0.00% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% Rocket One Inc. Common Stock N/A -165.25% -143.61%

Does the media favor ASBP or RKTO?

In the previous week, Aspire Biopharma and Aspire Biopharma both had 2 articles in the media. Aspire Biopharma's average media sentiment score of 0.38 beat Rocket One Inc. Common Stock's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket One Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ASBP or DYAI?

Dyadic International has a consensus target price of $3.00, indicating a potential upside of 310.40%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media favor ASBP or DYAI?

In the previous week, Aspire Biopharma had 1 more articles in the media than Dyadic International. MarketBeat recorded 2 mentions for Aspire Biopharma and 1 mentions for Dyadic International. Aspire Biopharma's average media sentiment score of 0.38 beat Dyadic International's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aspire Biopharma (ASBP) Competitors

$6.54 +0.37 (+6.00%)

Closing price 04:00 PM Eastern

Extended Trading

$6.30 -0.24 (-3.69%)

As of 07:37 PM Eastern

Compare

ASBP vs. TXMD, QUCY, LITS, RKTO, and DYAI

Should you buy Aspire Biopharma stock or one of its competitors? MarketBeat compares Aspire Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aspire Biopharma include TherapeuticsMD (TXMD), Mainz Biomed (QUCY), Lite Strategy (LITS), Rocket One Inc. Common Stock (RKTO), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry.

How does Aspire Biopharma compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.70	-$570K	$0.06	33.50
Aspire Biopharma	$10K	850.20	-$24.48M	-$116.67	N/A

In the previous week, Aspire Biopharma had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for Aspire Biopharma and 0 mentions for TherapeuticsMD. Aspire Biopharma's average media sentiment score of 0.38 beat TherapeuticsMD's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Aspire Biopharma	Neutral

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TherapeuticsMD has a net margin of 5.34% compared to Aspire Biopharma's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Aspire Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Aspire Biopharma	N/A	N/A	-398.04%

TherapeuticsMD has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

Summary

TherapeuticsMD beats Aspire Biopharma on 9 of the 13 factors compared between the two stocks.

How does Aspire Biopharma compare to Mainz Biomed?

Aspire Biopharma (NASDAQ:ASBP) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
Mainz Biomed	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Mainz Biomed has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	850.20	-$24.48M	-$116.67	N/A
Mainz Biomed	$540K	39.50	-$16.21M	-$47.60	N/A

19.2% of Aspire Biopharma shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by insiders. Comparatively, 3.1% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aspire Biopharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market.

In the previous week, Mainz Biomed had 1 more articles in the media than Aspire Biopharma. MarketBeat recorded 3 mentions for Mainz Biomed and 2 mentions for Aspire Biopharma. Aspire Biopharma's average media sentiment score of 0.38 beat Mainz Biomed's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mainz Biomed beats Aspire Biopharma on 8 of the 12 factors compared between the two stocks.

How does Aspire Biopharma compare to Lite Strategy?

Aspire Biopharma (NASDAQ:ASBP) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Aspire Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aspire Biopharma's return on equity of 0.00% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
Lite Strategy	N/A	-90.81%	-89.33%

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 52.4% of Lite Strategy shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 1.6% of Lite Strategy shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lite Strategy has higher revenue and earnings than Aspire Biopharma. Lite Strategy is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	850.20	-$24.48M	-$116.67	N/A
Lite Strategy	$65.30M	0.45	-$15.94M	-$1.60	N/A

In the previous week, Lite Strategy had 3 more articles in the media than Aspire Biopharma. MarketBeat recorded 5 mentions for Lite Strategy and 2 mentions for Aspire Biopharma. Lite Strategy's average media sentiment score of 0.57 beat Aspire Biopharma's score of 0.38 indicating that Lite Strategy is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lite Strategy	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lite Strategy beats Aspire Biopharma on 8 of the 12 factors compared between the two stocks.

How does Aspire Biopharma compare to Rocket One Inc. Common Stock?

Aspire Biopharma (NASDAQ:ASBP) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, Aspire Biopharma and Aspire Biopharma both had 2 articles in the media. Aspire Biopharma's average media sentiment score of 0.38 beat Rocket One Inc. Common Stock's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket One Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rocket One Inc. Common Stock has lower revenue, but higher earnings than Aspire Biopharma. Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	850.20	-$24.48M	-$116.67	N/A
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A

Aspire Biopharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, Rocket One Inc. Common Stock has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 6.9% of Rocket One Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Rocket One Inc. Common Stock has a consensus price target of $5.00, indicating a potential upside of 395.05%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Rocket One Inc. Common Stock is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aspire Biopharma's return on equity of 0.00% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

Summary

Rocket One Inc. Common Stock beats Aspire Biopharma on 8 of the 13 factors compared between the two stocks.

How does Aspire Biopharma compare to Dyadic International?

Aspire Biopharma (NASDAQ:ASBP) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aspire Biopharma has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Aspire Biopharma's return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Aspire Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Dyadic International has a consensus target price of $3.00, indicating a potential upside of 310.40%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Aspire Biopharma had 1 more articles in the media than Dyadic International. MarketBeat recorded 2 mentions for Aspire Biopharma and 1 mentions for Dyadic International. Aspire Biopharma's average media sentiment score of 0.38 beat Dyadic International's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyadic International has higher revenue and earnings than Aspire Biopharma. Dyadic International is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	850.20	-$24.48M	-$116.67	N/A
Dyadic International	$3.09M	8.62	-$7.36M	-$0.23	N/A

Summary

Dyadic International beats Aspire Biopharma on 10 of the 16 factors compared between the two stocks.

Get Aspire Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASBP vs. The Competition

Export

Metric	Aspire Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.99M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-0.06	20.50	25.39	23.96
Price / Sales	850.20	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	-0.12	8.26	10.76	6.41
Net Income	-$24.48M	$23.91M	$3.56B	$337.14M
7 Day Performance	2.83%	3.05%	1.37%	-0.48%
1 Month Performance	20.89%	2.40%	0.81%	0.49%
1 Year Performance	-98.00%	56.35%	30.53%	28.16%

Aspire Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASBP Aspire Biopharma	0.1627 of 5 stars	$6.54 +6.0%	N/A	-98.2%	$7.99M	$10K	N/A	N/A	News Coverage
TXMD TherapeuticsMD	0.7838 of 5 stars	$2.20 +20.9%	N/A	+80.2%	$25.46M	$3.35M	36.67	420	Positive News High Trading Volume
QUCY Mainz Biomed	0.3946 of 5 stars	$1.73 -8.9%	N/A	N/A	$25.36M	$540K	N/A	30	News Coverage
LITS Lite Strategy	0.8435 of 5 stars	$0.74 +0.2%	N/A	N/A	$25.22M	$65.30M	N/A	100	News Coverage
RKTO Rocket One Inc. Common Stock	1.4585 of 5 stars	$1.12 -24.7%	$5.00 +348.4%	-15.9%	$24.89M	N/A	N/A	4	Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASBP) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aspire Biopharma (ASBP) Competitors

ASBP vs. TXMD, QUCY, LITS, RKTO, and DYAI

How does Aspire Biopharma compare to TherapeuticsMD?

Summary

How does Aspire Biopharma compare to Mainz Biomed?

Summary

How does Aspire Biopharma compare to Lite Strategy?

Summary

How does Aspire Biopharma compare to Rocket One Inc. Common Stock?

Summary

How does Aspire Biopharma compare to Dyadic International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aspire Biopharma (ASBP) Competitors

ASBP vs. TXMD, QUCY, LITS, RKTO, and DYAI

How does Aspire Biopharma compare to TherapeuticsMD?

Do analysts recommend TXMD or ASBP?

Which has higher earnings & valuation, TXMD or ASBP?

Does the media prefer TXMD or ASBP?

Do institutionals & insiders believe in TXMD or ASBP?

Is TXMD or ASBP more profitable?

Which has more risk and volatility, TXMD or ASBP?

Summary

How does Aspire Biopharma compare to Mainz Biomed?

Is ASBP or QUCY more profitable?

Do analysts prefer ASBP or QUCY?

Which has stronger earnings & valuation, ASBP or QUCY?

Do institutionals and insiders have more ownership in ASBP or QUCY?

Which has more risk & volatility, ASBP or QUCY?

Does the media favor ASBP or QUCY?

Summary

How does Aspire Biopharma compare to Lite Strategy?

Which has more volatility & risk, ASBP or LITS?

Do analysts prefer ASBP or LITS?

Is ASBP or LITS more profitable?

Do insiders and institutionals believe in ASBP or LITS?

Which has stronger valuation and earnings, ASBP or LITS?

Does the media favor ASBP or LITS?

Summary

How does Aspire Biopharma compare to Rocket One Inc. Common Stock?

Does the media favor ASBP or RKTO?

Which has higher valuation & earnings, ASBP or RKTO?

Which has more risk & volatility, ASBP or RKTO?

Do institutionals and insiders believe in ASBP or RKTO?

Do analysts prefer ASBP or RKTO?

Is ASBP or RKTO more profitable?

Summary

How does Aspire Biopharma compare to Dyadic International?

Do insiders & institutionals believe in ASBP or DYAI?

Is ASBP or DYAI more profitable?

Which has more volatility & risk, ASBP or DYAI?

Do analysts recommend ASBP or DYAI?

Does the media favor ASBP or DYAI?

Which has stronger valuation & earnings, ASBP or DYAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools